12/22/2022, Newark // Future Market Insights, Inc. //

The  3D cell culture market  revenues surpassed US$ 778 million in 2018, as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,

Leading Manufacturers in the 3D Cell Culture Market:

• Thermo Fisher Scientific Inc.,
• Merck KGaA,
• Becton,
• Dickinson and Company, and Lonza,
• Corning Incorporated,
• Synthecon, Inc.

Competitive Landscape of the Global 3D Cell Culture MarketThe competition section of the 3D cell culture market represents the profiles of the key players operating in the 3D cell culture market based on the products they offer and the total revenue of the companies. Some of the key players featured in this report include Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Lonza, and Corning Incorporated.The key manufacturers of 3D cell culture offer a wide range of products. Thermo Fisher Scientific, Inc. has developed a joint platform for advancing research in precision medicine.Corning, one of the major leaders in 3D cell culture market, manufactures cell culture products, which include consumables (such as plastic vessels, specialty surfaces, cell culture media, and serum), as well as general labware and equipment, which are used for advanced cell culture research.Download PDF Brochure @  Application of 3D Cell Culture in Cancer Research ProminentThe FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.Stem cell technology is another lucrative field for 3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from a few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine, and drug discovery.Revenues in North America Continue to SurgeNorth America continued to spearhead the revenues of 3D cell culture market during the historical period and the status-quo is likely to continue in the future. In 2018, North America accounted for over two-fifths of the global 3D cell culture market revenues. The study estimates that regional revenues are expected to grow at 8% in 2019 over 2018.Funding in research and development, especially in cancer research remains higher in the United States as compared to other developed countries. Europe also presents significant funding in R&D activities. The FMI study finds that over one-fourth of the 3D cell culture market revenues were accounted for the Europe region in 2018, of which a bulk of revenues come from Western European countries such as Germany, the UK, France, Italy and Spain.Key Segment Based on product type

• scaffold-free 3D cell culture
• scaffold-based 3D cell culture

Based on application

• drug discovery
• tissue regeneration & regenerative medicines
• cancer research
• stem cell technology
• others

Based on end user

• biotechnology and pharmaceuticals industries
• hospital laboratories
• academic research and institutes
• contract research organizations

More Trending Reports by Future Market Research: : Global liquid biopsy market demand is anticipated to be valued at US$ 1,146 Million in 2022, forecast a CAGR of 13.49% to be valued at US$ 4,126 Million from 2022 to 2032. : The global Digital Patient Monitoring Systems market is estimated at US$ 96.4 Bn in 2022 and is projected to reach a valuation of US$ 470 Bn by 2032, expanding at a CAGR of 17.2% through the forecast period of 2022-2032. : The medical drones market is anticipated to flourish in the worldwide market at a strong CAGR of 24.3% during the forecast period, reaching a revenue of US$ 280.6 Mn in 2022 : The oncology information systems market is projected to be worth US$ 2.59 Bn by 2022 and is expected to grow to US$5.4 Bn by 2032, at a CAGR of 7.8% from 2022 to 2032. About FMI:Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.Contact Us: Future Market Insights, Unit No: 1602-006, Jumeirah Bay 2, Plot No: JLT-PH2-X2A, Jumeirah Lakes Towers, Dubai, United Arab Emirates For Sales Enquiries:  Website:  |  | 

The post 3D Cell Culture Market is estimated to exhibit a CAGR of 9.8% during the forecast period (2022-2031). appeared first on Future Market Insights.

Source: Future Market Insights, Inc.

Release ID: 473210

Original Source of the original story >> 3D Cell Culture Market is estimated to exhibit a CAGR of 9.8% during the forecast period (2022-2031).

This content is published on behalf of the above source. Please contact them directly for any concern related to the above. 

This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.